Free Trial Information
BioCentury | Nov 18, 2016
Company News

Management tracks

...from VP of business development and strategy. He replaces the retiring John Bakewell. Neurology company vasopharm GmbH...
Read More
BioCentury | Sep 12, 2016
Clinical News

Ronopterin: Phase III started

...48 hours in 232 patients who suffered a moderate to severe TBI within 6-18 hours. vasopharm GmbH...
Read More
BioCentury | Jan 25, 2016
Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany Business: Cardiovascular, Inflammation, Neurology Date completed: 2016-01-21 Type: Venture financing Raised: EUR20 million ($21.8 million) Investors: Entrepreneurs Fund; Heidelberg Capital; Fort Rock Capital; Bayern Kapital; Hanseatic Asset Management WIR Staff Cardiovascular...
Read More
BioCentury | Jan 22, 2016
Financial News

vasopharm raises EUR 20M

...Rock Capital. Existing investors Bayern Kapital and funds advised by Hanseatic Asset Management also participated. vasopharm...
...arterial occlusive diseases. vasopharm did not respond to inquiries. Fort Rock's Mario Accardi will join vasopharm's...
Read More
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: Nitric oxide (NO) synthase; interleukin-10 (IL-10)

...the combination of radiation plus inhibition of NO synthase or IL-10 in additional tumor models. vasopharm GmbH...
Read More
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...SAGE-547 GABA A receptor PAM Phase II Postpartum depression; essential tremor; refractory status epilepticus None vasopharm GmbH...
Read More
BioCentury | Jul 1, 2013
Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany Business: Cardiovascular, Neurology Date completed: 6/24/13 Type: Venture financing Raised: €5 million ($6.6 million) Investors: HeidelbergCapital; Entrepreneurs Fund; Bayern Kapital; Hanseatic Asset Management; company director Note: The financing is a series...
Read More
BioCentury | Sep 24, 2012
Clinical News

VAS203: Final Phase IIa data

...the VAS203 arm compared to a mortality rate of 12.5% in the placebo arm. Additionally, vasopharm...
...disclose details. VAS203 has Orphan Drug designation in Europe to treat moderate and severe TBI. vasopharm GmbH...
Read More
BioCentury | Oct 7, 2010
Distillery Therapeutics

Indication: Neurology

...or using vehicle control. Next steps include optimizing the pharmacokinetics and selectivity of NOX4-targeting compounds. vasopharm GmbH's...
Read More
BioCentury | Jan 29, 2009
Distillery Therapeutics

Indication: Inflammation

...II testing to treat asthma and rheumatoid arthritis (RA). VAS203, a NO synthase inhibitor from vasopharm GmbH...
Read More
Items per page:
1 - 10 of 15
BioCentury | Nov 18, 2016
Company News

Management tracks

...from VP of business development and strategy. He replaces the retiring John Bakewell. Neurology company vasopharm GmbH...
Read More
BioCentury | Sep 12, 2016
Clinical News

Ronopterin: Phase III started

...48 hours in 232 patients who suffered a moderate to severe TBI within 6-18 hours. vasopharm GmbH...
Read More
BioCentury | Jan 25, 2016
Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany Business: Cardiovascular, Inflammation, Neurology Date completed: 2016-01-21 Type: Venture financing Raised: EUR20 million ($21.8 million) Investors: Entrepreneurs Fund; Heidelberg Capital; Fort Rock Capital; Bayern Kapital; Hanseatic Asset Management WIR Staff Cardiovascular...
Read More
BioCentury | Jan 22, 2016
Financial News

vasopharm raises EUR 20M

...Rock Capital. Existing investors Bayern Kapital and funds advised by Hanseatic Asset Management also participated. vasopharm...
...arterial occlusive diseases. vasopharm did not respond to inquiries. Fort Rock's Mario Accardi will join vasopharm's...
Read More
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: Nitric oxide (NO) synthase; interleukin-10 (IL-10)

...the combination of radiation plus inhibition of NO synthase or IL-10 in additional tumor models. vasopharm GmbH...
Read More
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...SAGE-547 GABA A receptor PAM Phase II Postpartum depression; essential tremor; refractory status epilepticus None vasopharm GmbH...
Read More
BioCentury | Jul 1, 2013
Financial News

vasopharm completes venture financing

vasopharm GmbH , Wuerzburg, Germany Business: Cardiovascular, Neurology Date completed: 6/24/13 Type: Venture financing Raised: €5 million ($6.6 million) Investors: HeidelbergCapital; Entrepreneurs Fund; Bayern Kapital; Hanseatic Asset Management; company director Note: The financing is a series...
Read More
BioCentury | Sep 24, 2012
Clinical News

VAS203: Final Phase IIa data

...the VAS203 arm compared to a mortality rate of 12.5% in the placebo arm. Additionally, vasopharm...
...disclose details. VAS203 has Orphan Drug designation in Europe to treat moderate and severe TBI. vasopharm GmbH...
Read More
BioCentury | Oct 7, 2010
Distillery Therapeutics

Indication: Neurology

...or using vehicle control. Next steps include optimizing the pharmacokinetics and selectivity of NOX4-targeting compounds. vasopharm GmbH's...
Read More
BioCentury | Jan 29, 2009
Distillery Therapeutics

Indication: Inflammation

...II testing to treat asthma and rheumatoid arthritis (RA). VAS203, a NO synthase inhibitor from vasopharm GmbH...
Read More
Items per page:
1 - 10 of 15